Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + methylprednisolone
- Development stage
- Phase 4
- Lead developer
- Peking University People's Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Methotrexate combined with methylprednisolone is an investigational therapeutic regimen being evaluated as a first-line treatment for grade II-IV acute graft-versus-host disease (aGVHD) in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT). Developed and studied primarily by researchers at Peking University People's Hospital, this combination therapy utilizes low-dose (mini-dose) methotrexate as an adjunct to standard corticosteroid therapy (methylprednisolone). Methotrexate is a small molecule antimetabolite that inhibits dihydrofolate reductase, thereby interfering with DNA synthesis and suppressing the proliferation of T-cells involved in the alloimmune response. Methylprednisolone, a synthetic glucocorticoid, provides potent anti-inflammatory and immunosuppressive effects by activating the glucocorticoid receptor. The combination is intended to enhance the efficacy of standard steroid therapy and improve complete response rates in patients with aGVHD.
- Other names
- mini-dose methotrexatemethotrexate and methylprednisoloneMTX + corticosteroid
02
Targets
ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)DHFR (Dihydrofolate reductase)GR (Glucocorticoid receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on methotrexate + methylprednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + methylprednisolone.